BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33183271)

  • 1. The value of haematological parameters and serum tumour markers for predicting KRAS mutations in 784 Chinese colorectal cancer patients: a retrospective analysis.
    Cao Y; Gu J; Yan L; Deng S; Mao F; Cai W; Li H; Liu X; Wang J; Wu K; Cai K
    BMC Cancer; 2020 Nov; 20(1):1099. PubMed ID: 33183271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of
    Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
    Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
    Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
    Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
    Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations.
    Li W; Qiu T; Ling Y; Guo L; Li L; Ying J
    Oncotarget; 2015 Nov; 6(37):39607-13. PubMed ID: 26530529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients.
    Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H
    Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of KRAS Mutation Status Prediction Model for Colorectal Cancer Based on Medical Imaging.
    Ren Z; Che J; Wu XW; Xia J
    Comput Math Methods Med; 2021; 2021():3953442. PubMed ID: 34976107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of Haematological Parameters and Tumour Markers in the Prediction of Intestinal Obstruction in 1474 Chinese Colorectal Cancer Patients.
    Cao Y; Ke S; Gu J; Mao F; Yao S; Deng S; Yan L; Wu K; Liu L; Cai K
    Dis Markers; 2020; 2020():8860328. PubMed ID: 32855747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach.
    Taguchi N; Oda S; Yokota Y; Yamamura S; Imuta M; Tsuchigame T; Nagayama Y; Kidoh M; Nakaura T; Shiraishi S; Funama Y; Shinriki S; Miyamoto Y; Baba H; Yamashita Y
    Eur J Radiol; 2019 Sep; 118():38-43. PubMed ID: 31439256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT Texture Analysis: A Potential Biomarker for Evaluating KRAS Mutational Status in Colorectal Cancer.
    Cao J; Wang GR; Wang ZW; Jin ZY
    Chin Med Sci J; 2020 Dec; 35(4):306-314. PubMed ID: 33413746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
    Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
    Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.